Research Article Open Access

NEWER DRUGS FOR VISCERAL LEISHMANIASIS: A REVIEW

Krishna Pandey1, Dharmendra Singh1, Sanjiva Bimal1, Vidyanand Rabidas1, Krishna Murti1, Chadrashekhar Lal2 and P. Das1
  • 1 Rajendra Memorial Research Institute of Medical Sciences, India
  • 2 National Institute of Pharmaceutical Education and Research, India

Abstract

Visceral Leishmaniasis (VL) is one of the most neglected tropical diseases worldwide. The diagnosis and treatment of this disease is quite complex. Sodium Antimony Gluconate (SAG) which used to be a very effective treatment has now developed resistance and is potentially a cardio-toxic drug. Pentamidine has now been discarded because of adverse effect of diabetes mellitus. Amphotericin-B is an effective drug but can cause nephrotoxicity. Miltefosine is a new oral effective drug which has recently been introduced in the kala-azar elimination program in the Indian subcontinent. Paromomycin is an injectable aminoglycoside which is quite cheap but can cause ototoxicity and nephrotoxicity. Sitamaquine, an oral antimalarial drug is still in phase-II trial stage. Combination Therapy is been tried with good results. Single dose Ambisome (liposomal Amphotericin-B) though costly is a very good alternative.

American Journal of Infectious Diseases
Volume 10 No. 2, 2014, 68-70

DOI: https://doi.org/10.3844/ajidsp.2014.68.70

Submitted On: 26 March 2014 Published On: 5 May 2014

How to Cite: Pandey, K., Singh, D., Bimal, S., Rabidas, V., Murti, K., Lal, C. & Das, P. (2014). NEWER DRUGS FOR VISCERAL LEISHMANIASIS: A REVIEW. American Journal of Infectious Diseases, 10(2), 68-70. https://doi.org/10.3844/ajidsp.2014.68.70

  • 3,862 Views
  • 2,735 Downloads
  • 5 Citations

Download

Keywords

  • Visceral Leishmaniasis
  • Miltefosine
  • Paromomycin
  • Sitamaquine
  • Combination Therapy
  • Ambisome